Ownership history in Eversept Partners, LP Β· 32 quarters on record
This page tracks every 13F SEC filing in which Eversept Partners, LP reported a position in GLAXOSMITHKLINE PLC (GSK). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Eversept Partners, LP underperformed the S&P 500 by β5.7% annually on this GSK position. Timing score: 41% (12/29 decisions correct). Average cost basis: $33.72. Maximum drawdown during holding period: β31.6%.
β Significantly underperformed the S&P 500 by 5.7% ann.
30 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
12 of 29 add/trim decisions correct
Best entry: $25.64 (2022 Q3) Β· Worst: $48.65 (2025 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
19 adds Β· 12 trims. Bought during 4 of 10 down-price quarters. π More buys than sells across the holding period.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 6.62% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size